Advertisement
A vs TMO
Which Stock Would AI Choose? Agilent Technologies (A) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- Agilent Technologies (A) and Thermo Fisher Scientific (TMO) operate in the life sciences tools and diagnostics sector, with TMO offering broader scale and diversified end markets compared to A's more focused analytical instrumentation portfolio.
- Recent market activity shows A trading in the $130–$138 range amid mixed quarterly results and sector demand fluctuations, while TMO has hovered near $530–$540 ahead of its Q2 2026 earnings release.
- Both companies reported mid-single-digit revenue growth in their most recent reported quarters, supported by core organic expansion and strategic acquisitions.
- TMO maintains a larger market capitalization and higher absolute earnings base, providing greater resilience but also exposing it to broader macroeconomic sensitivity in pharma and biotech spending.
- Sector sentiment remains influenced by instrument demand recovery and capital deployment strategies, with analysts maintaining generally positive ratings for both stocks.
- Relative performance highlights trade-offs between A's specialized exposure and TMO's scale advantages in a recovering research environment.
Introduction
Agilent Technologies (A) and Thermo Fisher Scientific (TMO) represent key players in the life sciences and analytical instrumentation space. Investors and traders often compare these stocks when evaluating exposure to laboratory tools, diagnostics, and research equipment amid evolving healthcare and pharmaceutical spending patterns. This analysis examines their business models, recent price behavior, and market positioning to assist those assessing relative value within the sector. The comparison is particularly relevant for portfolio managers seeking diversified life sciences holdings or traders monitoring momentum in healthcare technology names.
Agilent Technologies (A) Overview and Recent Performance
Agilent Technologies provides analytical instruments, software, and services primarily for life sciences, diagnostics, and applied chemical markets. In recent weeks, the stock has traded in a range influenced by broader sector demand for laboratory equipment and mixed quarterly results. Fiscal Q2 performance highlighted revenue growth in the mid-single digits on a core basis, driven by instrument demand, though earnings per share showed variability. Market activity reflects investor focus on recovery in research and development spending, with the share price positioned below its 52-week high amid ongoing economic considerations affecting
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a StrongBuy and TMO is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 2 FA rating(s) are green whileTMO’s FA Score has 1 green FA rating(s).
- A’s FA Score: 2 green, 3 red.
- TMO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 3 TA indicator(s) are bullish while TMO’s TA Score has 6 bullish TA indicator(s).
- A’s TA Score: 3 bullish, 3 bearish.
- TMO’s TA Score: 6 bullish, 4 bearish.
Price Growth
A (@Medical Specialties) experienced а +5.41% price change this week, while TMO (@Medical Specialties) price change was +6.72% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.55%. For the same industry, the average monthly price growth was +2.80%, and the average quarterly price growth was +1.12%.
Reported Earning Dates
A is expected to report earnings on Aug 18, 2026.
TMO is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Medical Specialties (-1.55% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| A | TMO | A / TMO | |
| Capitalization | 39.1B | 211B | 19% |
| EBITDA | 1.96B | 11.7B | 17% |
| Gain YTD | 2.449 | -1.736 | -141% |
| P/E Ratio | 27.83 | 30.58 | 91% |
| Revenue | 7.23B | 45.2B | 16% |
| Total Cash | 1.81B | 1.12B | 161% |
| Total Debt | 3.36B | 43.2B | 8% |
A | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 82 | 33 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 10 Undervalued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 80 | |
SMR RATING 1..100 | 44 | 62 | |
PRICE GROWTH RATING 1..100 | 19 | 40 | |
P/E GROWTH RATING 1..100 | 56 | 37 | |
SEASONALITY SCORE 1..100 | 75 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (10) in the Biotechnology industry is in the same range as TMO (12) in the Medical Specialties industry. This means that A’s stock grew similarly to TMO’s over the last 12 months.
TMO's Profit vs Risk Rating (80) in the Medical Specialties industry is in the same range as A (100) in the Biotechnology industry. This means that TMO’s stock grew similarly to A’s over the last 12 months.
A's SMR Rating (44) in the Biotechnology industry is in the same range as TMO (62) in the Medical Specialties industry. This means that A’s stock grew similarly to TMO’s over the last 12 months.
A's Price Growth Rating (19) in the Biotechnology industry is in the same range as TMO (40) in the Medical Specialties industry. This means that A’s stock grew similarly to TMO’s over the last 12 months.
TMO's P/E Growth Rating (37) in the Medical Specialties industry is in the same range as A (56) in the Biotechnology industry. This means that TMO’s stock grew similarly to A’s over the last 12 months.
| A | TMO | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 61% |
| Stochastic ODDS (%) | 2 days ago 72% | 2 days ago 60% |
| Momentum ODDS (%) | 2 days ago 64% | 2 days ago 59% |
| MACD ODDS (%) | 2 days ago 59% | 2 days ago 66% |
| TrendWeek ODDS (%) | 2 days ago 62% | 2 days ago 61% |
| TrendMonth ODDS (%) | 2 days ago 57% | 2 days ago 61% |
| Advances ODDS (%) | 3 days ago 60% | 3 days ago 61% |
| Declines ODDS (%) | 6 days ago 64% | 5 days ago 63% |
| BollingerBands ODDS (%) | 2 days ago 70% | 2 days ago 63% |
| Aroon ODDS (%) | N/A | 2 days ago 59% |
Advertisement